Aug 2026· Proceedings of the 32nd ACM SIGKDD Conference on Knowledge Discovery and Data Mining V.2· pp. 9871-9881· 0 citations· 44 references
TL;DR
SAASBench provides a framework for evaluating the model's ability to estimate the specificity of a candidate antibody in relevant settings, indicating that strong performance on traditional affinity benchmarks does not automatically translate into reliable antibody specificity estimation in proteome-derived settings.
Abstract
Accurate computational prediction of antibody-antigen binding affinity and specificity is critical for accelerating the design of next-generation therapeutics. In computational antibody design, the central challenge is not merely predicting binding, but determining whether an antibody preferentially binds its intended antigen over realistic off-targets. Existing antibody-antigen benchmarks largely focus on affinity prediction or docking accuracy on known binders, and therefore do not directly evaluate antibody specificity. We introduce SAASBench, an adversarial diagnostic benchmark that isolates antibody specificity as a set-based ranking problem. For 20 therapeutically approved full-length antibodies, SAASBench constructs an antibody-conditioned synthetic candidate set containing the true antigen and hard negative decoys drawn from the human extracellular proteome. The decoys are selected to be similar to the positive on structural plausibility of the synthetic Ab-Ag complex and on the change in solvent accessible surface area. Evaluation uses per-antibody ranking metrics aligned with practical downselection decisions. Across 20 antibody panels, affinity-based predictors display heterogeneous performance, ranging from below-random to moderate success. Overall, these results indicate that strong performance on traditional affinity benchmarks does not automatically translate into reliable antibody specificity estimation in proteome-derived settings. SAASBench provides a framework for evaluating the model's ability to estimate the specificity of a candidate antibody in relevant settings.
The AIntibody challenge shows that AI can optimize antibodies in defined, biologically grounded regimes, in addition to highlighting critical gaps including affinity prediction and library-inspired antibody design and cross-task generalization.
M. Erasmus, Daniel Bedinger, Elizabeth Hopkins et al.· Nature Biotechnology· 0 citations
The results show that current LLMs capture partial epitope-related signals but remain limited in antibody-specific sequence grounding, long-context residue localization, and biologically grounded reasoning, so EpiBench provides a diagnostic testbed for measuring and improving sequence-aware biomedical LLMs toward relia...
Zi-Rui Wang, Jiaqing Wang, Qing-Han Wang et al.· 0 citations
Deep-learning methods for antibody structure prediction, antibody-antigen interaction modelling and design are advancing rapidly. However, comparisons across studies remain difficult because training and test sets are often constructed independently, and a temporal cutoff alone does not prevent train-test leakage. We p...
Tomer Cohen, H. Bhattacharya, Michal Ozery-Flato et al.· bioRxiv· 0 citations
The most recent methods substantially outperformed earlier ones, producing medium-or-better top-ranked models for approximately half of post-cutoff Fv complexes without templates or experimental restraints, and performing similarly on antigens with or without a close pre-cutoff homolog.
Minjae Park, Roman Nett, Brian M. Petersen et al.· bioRxiv· 0 citations
Defining the binding epitopes of antibodies is essential for understanding how they bind to their antigens and perform their molecular functions. However, while determining linear epitopes of monoclonal antibodies can be accomplished utilizing well-established empirical procedures, these approaches are generally labor-...
Jacob DeRoo, J. S. Terry, Ning Zhao et al.· eLife· 0 citations
A lightweight post-hoc filter that requires no re-docking and is directly compatible with existing AF3 prediction pipelines and transferable to other diffusion-based complex predictors, providing a practical quality-assurance layer for antibody epitope mapping in early-stage drug discovery.
Xiao-Yu Liu, Yu Wang· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.